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Abstract: Quality of Life (QoL) is decreased in multiple sclerosis (MS), but studies about 
the impact of sleep disorders (SD) on health-related quality of Life (HRQoL) are lacking. 
From our original cohort, a cross-sectional polysomnographic (PSG) study in consecutive 
MS patients, we retrospectively analysed the previously unpublished data of the 
Nottingham Health Profile (NHP). Those MS patients suffering from sleep disorders  
(n = 49) showed significantly lower HRQoL compared to MS patients without sleep 
disorders (n = 17). Subsequently, we classified the patients into four subgroups: insomnia 
(n = 17), restless-legs syndrome, periodic limb movement disorder and SD due to leg pain 
(n = 24), obstructive sleep apnea (n = 8) and patients without sleep disorder (n = 17).  
OSA and insomnia patients showed significantly higher NHP values and decreased 
HRQoL not only for the sleep subscale but also for the “energy” and “emotional” area of 
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the NHP. In addition, OSA patients also showed increased NHP values in the “physical 
abilities” area. Interestingly, we did not find a correlation between the objective PSG 
parameters and the subjective sleep items of the NHP. However, this study demonstrates 
that sleep disorders can reduce HRQoL in MS patients and should be considered as an 
important confounder in all studies investigating HRQoL in MS. 
Keywords: restless legs syndrome; sleep disorders; multiple sclerosis; clinical 
neurophysiology; polysomnography; insomnia; pain; depression; health; quality of life 
 
1. Introduction 
Recently, we published the results of a cross-sectional polysomnographic (PSG) study in consecutive 
multiple sclerosis (MS) patients [1]. Of 66 patients who underwent PSG, 49 suffered from a sleep 
disorder (SD); seven of these suffered from more than one SD. In these cases we classified only the 
more severe SD. In our study, SDs were significantly related to fatigue; and a follow-up investigation 
showed that a consequent treatment of sleep disorders may improve fatigue in a subset of patients [2]. 
The improvement of MS fatigue after medical treatment of SD was seen in another follow up study as 
well [3]. With regards to the relationship between health related Quality of Life (HRQoL) and SD in 
MS patients, there are only a few studies: Neau et al. [4], as well as Sarraf et al. [5], classified MS 
patients into good sleepers and poor sleepers using the Pittsburgh Sleep Quality Index [6] (PSQI) 
(PSQI ≤ 5 vs. > 5). In their studies, poor sleepers showed a reduced HRQoL using the MS-QOL-54 [7]. 
To our knowledge, there is only one study investigating the relationship between SDs confirmed by 
PSG and HRQoL in MS: Trojan et al. demonstrated a decreased mental but not physical HRQoL in 
MS patients with SD [8] using the Short Form Health Survey (SF-36) [9]. 
To date, there is no study investigating the HRQoL in MS patients with the Nottingham Health Profile 
(NHP) [10]. The NHP is a valid and reliable indicator of subjective health status in physical, social and 
emotional areas [10]. The NHP consists of two parts (part 1 and 2). Only part 1 is weighted and is 
composed of six subscales (sleep, physical mobility, energy, pain, emotional reactions and social 
isolation); the maximum of any subscale is 100. As a result, the maximum of the NHP total score is 600 
(the higher the NHP values, the lower the HRQoL). The weighting of the 38 statements reflects the 
symptom severity and represents rather severe problems in order to avoid picking up a large number of 
false positives [10]. In the literature mine rescue workers show a very low global mean NHP score of 
8.8; fit elderly persons show a mean global NHP score of 12.4; whereas pregnant women at 37 weeks, 
fracture victims and chronically ill elderly patients (mean global NHP 127.0/129.6/156.4) show 
increased NHP values, and especially high values were obtained in patients with osteoarthrosis (mean 
global NHP 271.3) [10]. Verwimp et al. investigated 75 OSA patients [11] and found an increased 
global NHP median (218). In their study the negative perception in the “physical abilities” domain was 
effectively related to an objective low level of physical activity measured by actigraphy. 
In our previous cross-sectional trial we also collected NHP data, which had not been analysed and 
published before. The aim of this study is to describe these data and to investigate the relationship 
between SD and HRQoL in MS. 
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2. Results 
2.1. Patients 
We classified the 66 patients (21 men and 45 women aged 20–66 years) into four subgroups: no sleep 
disorder (NSD) (n = 17), insomnia (n = 17) (INS), periodic limb movement disorder (PLMD), restless 
legs syndrome (RLS) or SD due to leg pain (PLMD/RLS) (n = 24), and untreated obstructive sleep apnea 
(OSA) (n = 8). Expanded Disability Status Scale (EDSS) [12] values ranged from zero to eight. 
2.1.1. HRQoL in MS Patients with Sleep Disorders Compared to Patients without Sleep Disorders 
Table 1 shows the NHP values in patients without SD compared with those patients suffering from 
SD (all SD together). MS patients suffering from SD showed significantly increased NHP values, 
indicating poorer HRQoL using the Mann–Whitney-U-test. 
Table 1. NHP values in patients with and without sleep disorders. 
NHP Global Score 
and Subscales 
Average and Range All Patients 
Patients without 
Sleep Disorders 
Patients with 
Sleep Disorders 
Differences between 
the Two Subgroups 
NHP-Total 
Mean (±standard deviation) 146.1 (±119.8) 67.3 (±60.0) 175.2 (±123.6) p = 0.001 
Min–Max 0.0–78.7 0.0–188.6 0.0–413.7  
25–75 0.0–32.6 21.8–120.5 61.3–273.3  
median 126.4 34.8 175.5  
Physical abilities 
Mean (±standard deviation) 20.9 (±21.5) 10.2 (±14.7) 24.8 (±22.4) p = 0.010 
Min–Max 0.0–78.7 0.0–54.5 0.0–78.7  
25–75 0.0–32.6 0.0–22.0 10.8–36.5  
median 12.7 0.0 21.7  
Social isolation 
Mean (±standard deviation) 11.7 (±19.6) 3.6 (±8.0) 14.7 (±21.8) p = 0.048 
Min–Max 0.0–80.6 0.0–22.5 0.0–80.6  
25–75 0.0–20.1 0.0–0.0 0.0–22.5  
median 0.0 0.0 0.0  
Sleep 
Mean (±standard deviation) 29.3 (±29.5) 10.6 (±15.1) 36.2 (±30.6) p = 0.001 
Min–Max 0.0–100.0 0.0–50.4 0.0–100.0  
25–75 0.0–16.1 0.0–12.6 12.6–72.7  
median 50.4 0.0 28.7  
Pain 
Mean (±standard deviation) 15.8 (±24.8) 3.8 (±9.8) 20.2 (±27.2) p = 0.009 
Min–Max 0.0–100.0 0.0–32.3 0.0–100.0  
25–75 0.0–0.0 0.0–0.0 0.0–30.6  
median 26.0 0.0 9.9  
Energy 
Mean (±standard deviation) 48.9 (±40.9) 29.9 (±35.5) 55.8 (±40.9) p = 0.016 
Min–Max 0.0–100.0 0.0–100.0 0.0–100.0  
25–75 0.0–60.8 0.0–62.0 24.0–100.0  
median 100.0 0.0 62.0  
Emotional 
Mean (±standard deviation) 19.6 (±18.8) 9.3 (±12.2) 23.5 (±19.5) p = 0.006 
Min–Max 0.0–69.0 0.0–41.4 0.0–69.0  
25–75 0.0–30.9 0.0–18.6 5.3–41.4  
median 16.8 0.0 21.0  
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2.1.2. Comparison of the Global NHP Values (Global HRQoL) in the Four Subgroups 
The comparison of the global NHP (including all six subscales) in the four subgroups showed 
significantly lower NHP values in the NSD and PLMD/RLS patients compared to OSA and insomnia 
patients; whereas there were no significant differences between NSD and PLMD/RLS patients  
neither between OSA and insomnia patients (see Figure 1 and Table 2). This suggests that NSD and 
PLMD/RLS patients have a better global HRQoL compared to OSA or insomnia patients. 
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Figure 1. Nottingham Health Profile total values in the four subgroups. 
Table 2. NHP total score and NHP items in the different subgroups. 
NHP 
Values 
Average 
and Range 
All 
Patients 
NSD INS OSA PLM 
Differences between 
the Two Subgroups 
Total 
Mean (SD) 146.1 67.3 220.3 239.6 119.9 
NSD vs. OSA  
p = 0.003  
NSD vs. INS  
p < 0.0001  
INS vs. PLM  
p = 0.002  
OSA vs. PLM  
p = 0.042  
NSD vs. PLM  
p = 0.210  
OSA vs. INS  
p = 0.804 
Standard 
deviation 
119.8 60.0 88.2 136.2 123.7 
Min–Max 0.0–78.7 0.0–188.6 60.7–369.9 24.7–413.7 0.0–408.61 
25–75 0.0–32.6 21.8–120.5 147.0–276.0 180.8–393.3 29.7–174.4 
Median 126.4 34.8 212.3 194.9 75.8 
2.1.3. Comparison of the NHP Subscales in the Four Subgroups 
Figure 2 displays the NHP values in the different subgroups. The patients without sleep disorders 
showed the lowest NHP values in all items. The insomnia subgroup showed the highest values in the 
“sleep” item. Attention should also be paid to the high values concerning “energy” (and to a lower 
Int. J. Mol. Sci. 2015, 16 16518 
 
 
extent regarding “emotions”) in the insomnia and OSA subgroup. Please take into account the high 
values regarding “physical abilities” in the OSA subgroup. 
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Figure 2. Subscales of the NHP in the different sleep disorders (mean values). 
Kruskal–Wallis-Test 
We performed the non-parametric Kruskal–Wallis-Test for comparing the four subgroups with 
different sample sizes. The Kruskal–Wallis-Test showed significant differences between the four 
subgroups for all items except for “social isolation”, meaning that this item seemed not to be different 
in the four subgroups—therefore, this item was not included in the further analysis (see Table 3). 
Table 3. Kruskal–Wallis-Test. 
NHP Total Physical Abilities Social Isolation Sleep Pain Energy Emotional
p < 0.0001 p = 0.007 p = 0.054 p = 0.001 p = 0.034 p < 0.0001 p < 0.0001 
Mann–Whitney-U-Test 
We subsequently analysed the NHP subscales (except for “social isolation”): a Mann–Whitney-U-test 
was performed in order to analyse the differences between two specific subgroups (OSA–PLM/ 
OSA–INS/OSA–NSD/PLM–INS/PLM–NSD/INS–NSD). Five items (physical abilities, sleep, pain, 
energy, emotional) remained in the further analysis (see Table 3). 
In four subscales (physical abilities, sleep, energy, emotional) we found significantly lower NHP 
values in NSD patients compared to insomnia and OSA patients (in the pain area there was only  
a significant difference between NSD patients and insomnia patients—but not between NSD patients  
and OSA patients) (see Table 4). This means that the HRQoL in these specific areas was higher in  
MS patients without comorbid sleep disorders compared to MS patients suffering from comorbid OSA 
or insomnia. 
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Table 4. NHP subscale values in all patients and in the four subgroups. 
Subscales Average and Range All Patients NSD INS OSA PLM 
Differences between 
the Two Subgroups  
Physical 
abilities 
Mean (Standard deviation) 20.9 (21.5) 10.2 (14.7) 27.4 (20.8) 41.0 (24.3) 17.7 (20.8) NSD vs. OSA p = 0.003 
NSD vs. INS p = 0.009 
INS vs. PLM p = 0.138 
OSA vs. PLM p = 0.032 
NSD vs. PLM p = 0.211 
OSA vs. INS p = 0.260 
Min–Max 0.0–78.7 0.0–54.5 0.0–77.3 10.8–78.2 0.0–78.7 
25–75 0.0–32.6 0.0–21.9 10.8–42.6 21.7–67.2 0.0–25.8 
Median 12.7 0.0 22.0 32.6 11.2 
Social 
isolation 
Mean (Standard deviation) 11.7 (19.6) 3.6 (8.0) 12.8 (19.0) 29.5 (31.0) 11.6 (19.4) 
For this subgroup no 
Mann–Whitney-U-Test 
was performed  
(see Table 2) 
Min–Max 0.0–80.6 0.0–22.5 0.0–64.7 0.0–80.6 0.0–63.9 
25–75 0.0–20.1 0.0–0.0 0.0–22.5 0.0–63.9 0.0–20.2 
Median 0.0 0.0 0.0 20.1 0.0 
Sleep 
Mean (Standard deviation) 29.3 (29.5) 10.6 (15.2) 48.7 (26.7) 26.8 (27.4) 29.5 (32.4) NSD vs. OSA p = 0.087 
NSD vs. INS p < 0.0001 
INS vs. PLM p = 0.048 
OSA vs. PLM p = 0.980 
NSD vs. PLM p = 0.063 
OSA vs. INS p = 0.075 
Min–Max 0.0–100.0 0.0–50.4 0.0–77.6 0.0–77.6 0.0–100 
25–75 0.0–16.1 0.0–12.6 25.2–75.2 12.6–50.4 0.0–50.4 
Median 50.4 0.0 50.4 12.6 14.3 
Pain 
Mean (Standard deviation) 15.8 (24.8) 3.8 (9.8) 21.9 (23.9) 27.0 (31.4) 16.6 (28.9) NSD vs. OSA p = 0.114 
NSD vs. INS p = 0.012 
INS vs. PLM p = 0.221 
OSA vs. PLM p = 0.469 
NSD vs. PLM p = 0.117 
OSA vs. INS p = 0.804 
Min–Max 0.0–100.0 0.0–32.7 0.0–69.8 0.0–80.2 0.0–100.0 
25–75 0.0–0.0 0.0–0.0 0.0–40.1 0.0–56.9 0.0–18.6 
Median 26.0 0.0 15.8 26.0 0.0 
Energy 
Mean (Standard deviation) 48.9 (40.9) 29.9 (35.5) 78.5 (28.7) 80.5 (38.0) 30.5 (35.4) NSD vs. OSA p = 0.007 
NSD vs. INS p < 0.0001 
INS vs. PLM p < 0.0001 
OSA vs. PLM p = 0.013 
NSD vs. PLM p = 0.790 
OSA vs. INS p = 0.710 
Min–Max 0.0–100.0 0.0–100.0 24.0–100.0 0.0–100.0 0.0–100.0 
25–75 0.0–60.8 0.0–62.0 60.8–100.0 63.2–100.0 0.0–61.4 
Median 100.0 0.0 100.0 100.0 24.0 
Emotional 
Mean (Standard deviation) 19.6 (18.8) 9.3 (12.2) 30.9 (19.8) 34.8 (16.8) 14.1 (15.9) NSD vs. OSA p = 0.001 
NSD vs. INS p = 0.001  
INS vs. PLM p = 0.007 
OSA vs. PLM p = 0.008 
NSD vs. PLM p = 0.392 
OSA vs. INS p = 0.619 
Min–Max 0.0–69.0 0.0–41.4 0.0–69.0 13.6–55.9 0.0–48.5 
25–75 0.0–30.9 0.0–18.6 14.1–47.1 17.0–52.0 0.0–22.7 
Median 16.8 0.0 30.9 30.9 10.9 
In sum, the differences between the OSA and insomnia subgroups were very small and not 
significant. Similarly, the differences between NSD and the PLMD/RLS patients were negligible. 
Significant clinical relevant differences were found comparing NSD and the PLMD/RLS patients to 
OSA and insomnia patients. 
The comparison between PLMD/RLS patients and insomnia patients showed significantly increased 
NHP values in the “sleep” subscale and highly significant increased NHP values in the “energy” and 
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“emotional” subscale. That means that insomnia patients showed a reduced HRQoL in these areas 
compared to PLMD/RLS patients. 
When comparing PLMD/RLS patients with OSA patients, there were significantly higher NHP values 
in OSA patients (decreased HRQoL) in the “physical abilities”, “energy” and “emotional” subscales. 
2.1.4. Comparison of the Objective (PSG) Sleep Parameters and the NHP Sleep Items 
The sleep subscales consist of five items: “I sleep badly at night”, “I lie awake for most of the 
night”, “It takes me a long time to get to sleep”, “I’m waking up in the early hours of the morning”,  
“I take pills to help me sleep”. Except for the last item (“I take pills to help me sleep”), we compared 
the other four items with PSG parameters using the Mann–Whitney-U-test: Table 5 shows the results: 
Table 5. Comparison of polysomnographic data and NHP sleep items. 
Items Average and Range 
Sleep 
Efficiency 
Awakenings Arousal-Index 
Sleep 
Latency 
Wake after 
Sleep Onset 
I sleep badly at night  
YES 
Mean (±standard deviation) 73.6 (±12.6) 25.5 (±7.7) 18.5 (±9.6)   
Min–Max 50–94 9–41 3.9–43.9   
25–75 63.7–83.5 20–30.5 12.2–22.9   
median 74.8 26.0 16.5   
I sleep badly at night  
NO 
Mean (±standard deviation) 76.7 (±16.2) 27.5 (±14.2) 20.5 (±10.0)   
Min–Max 8–93 8–72 1.1–47.1   
25–75 73.0–87.1 17.8–33.3 14.4–24.9   
median 80.45 26.0 21.7   
Differences between YES and NO p = 0.148 p = 0.860 p = 0.255   
I lie awake for most 
of the night  
YES 
Mean (±standard deviation) 76.2 (±15.0)     
Min–Max 8–93     
25–75 69.8–87.0     
median 79.7     
I lie awake for most 
of the night  
NO 
Mean (±standard deviation) 71.1 (±13.5)     
Min–Max 50–94     
25–75 60.0–80.7     
median 69.6     
Differences between YES and NO p = 0.175     
It takes me a long 
time to get to sleep  
YES 
Mean (±standard deviation)    38.5 (±39.8)  
Min–Max    2–198  
25–75    15.3–49.5  
median    29.0  
It takes me a long 
time to get to sleep  
NO 
Mean (±standard deviation)    26.4 (±31.1)  
Min–Max    0–190  
25–75    11.0–32.0  
median    21.0  
Differences between YES and NO    p = 0.08  
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Table 5. Cont. 
Items Average and Range 
Sleep 
Efficiency 
Awakenings Arousal-Index 
Sleep 
Latency 
Wake after 
Sleep Onset 
I’m waking up in the 
early hours of  
the morning  
YES 
Mean (±standard deviation)     88.4 (±59.0) 
Min–Max     27–258 
25–75     43.0–73.0 
median     73.0 
I’m waking up in the 
early hours of  
the morning  
NO 
Mean (±standard deviation)     69.8 (±41.4) 
Min–Max     20–173 
25–75     43.3–88.8 
median     52.5 
Differences between YES and NO     p = 0.336 
When we compared “It takes me a long time to get to sleep” to the sleep latency measured by PSG, 
there was no significant correlation between this subjective (NHP) and objective (PSG) measurement 
of sleep latency. Furthermore, we did not find any correlation between “I sleep badly at night” and 
sleep efficiency measured by PSG. Similarly the item “I’m waking up in the early hours of the 
morning” did not correlate with wake-after-sleep-onset in the PSG nor arousal-index or awakenings. 
2.2. Correlation between NHP Values and Other Questionnaires 
Table 6 shows the non-parametric correlations (Spearman–Rho) between NHP and other self-assessed 
questionnaires (Modified Fatigue Impact Scale (MFIS) [13]; Beck Depression Inventory (BDI) [14]; 
Pittsburgh Sleep Quality Index (PSQI) [6]). 
Table 6. Non parametric correlations (Spearman-Rho) between NHP and other questionnaires 
(Beck Depression Inventory and Pittsburgh Sleep Quality Index). 
NHP and MFIS NHP and BDI NHP and PSQI 
p < 0.0001 p < 0.0001 p < 0.0001 
r = 0.737 r = 0.836 r = 0.612 
The scatter plots visualize these findings. There was a significant correlation between NHP values 
and MFIS values—meaning that higher fatigue values are associated with reduced HRQoL (Figure 3). 
In addition, higher NHP values (reduced HRQoL) were also associated with higher depression values 
(BDI, Figure 4) and higher PSQI values (low sleep quality, Figure 5). This indicates that reduced 
HRQoL is associated with depression, fatigue, and bad sleep quality. 
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Figure 3. Correlation between NHP and MFIS values. Abbreviations: NHP = Nottingham 
Health Profile; MFIS = Modified Fatigue Impact Scale [13]. 
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Figure 4. Correlation between NHP and BDI values. Abbreviations: NHP = Nottingham 
Health Profile; BDI = Beck Depression Inventory [14]. 
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Figure 5. Correlation between NHP and PSQI values. Abbreviations: NHP = Nottingham 
Health Profile; PSQI = Pittsburgh Sleep Quality Index [6]. 
Correlation between NHP Values and the MFIS Subscales 
Furthermore, we investigated the correlation between the NHP global score and the three subscales 
of the MFIS (cognition, psychosocial and physical): a significant correlation was found between the 
global HRQoL (NHP values) and psychosocial aspects of fatigue, as well cognitive fatigue and 
physical fatigue (see Table 7): 
Table 7. Non-parametric correlations (Spearman–Rho) between NHP and the fatigue subscales. 
NHP and Cognitive MFIS-Subscale NHP and Physical MFIS-Subscale NHP and Psychosocial MFIS-Subscale 
p < 0.0001 p < 0.0001 p < 0.0001 
r = 0.635 r = 0.726 r = 0.548 
Abbreviations: NHP = Nottingham Health Profile; MFIS = Modified Fatigue Impact Scale. 
3. Discussion 
Our study demonstrates poor HRQoL in MS patients suffering from sleep disorders confirmed by 
PSG—especially from OSA and insomnia. The global NHP median was marginally lower in MS 
patients suffering from OSA (194.9) compared with OSA patients in the general population (218.0) [11]. 
Increased NHP values indicate severe health problems, and the mean global NHP score in MS patients 
with comorbid insomnia or OSA was higher than the mean scores described in the literature in 
pregnant women at 37 weeks, fracture victims and chronically ill elderly patients and almost as high as 
in patients with osteoarthrosis, whereas MS patients without sleep disorders show only moderately 
increased NHP values. OSA and insomnia can significantly reduce HRQoL in MS patients.  
MS patients suffering from PLMD, RLS or sleep disorders due to leg pain show a decreased HRQoL 
as well—although to a lesser extent. 
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The impairment of HRQoL in OSA and insomnia patients (besides the sleep problems) was more 
pronounced in the “energy” and “emotional” area. OSA patients are severely affected in the “physical 
abilities” as well (as described previously by Verwimp et al. in OSA patients without MS [11]). 
We cannot explain the lack of a correlation between the (objective) PSG parameter and the 
(subjective) sleep problems measured in the sleep subscale. This could be due to the fact that we 
investigated this relationship in different SDs (OSA, insomnia, PLMD/RLS). 
The decreased HRQoL in OSA and insomnia patients in the “energy” and “emotional” area argue 
for consecutive daytime symptoms due to the sleep disorders (and “physical abilities” in OSA patients 
as well). Here, it is difficult to explain what exactly drives these daytime symptoms. As recently 
reported [15], there is an overlap between fatigue, pain, depression, and sleep disorders. Moreover, OSA 
can lead to depression and continuous positive airway (CPAP) therapy can improve depression [16]. 
Insomnia has been found to be a clinical predictor of subsequent depression [17] and increased PSQI 
values are significantly associated with fatigue in MS patients [18]. To date, evidence-based therapies 
of MS-related fatigue are lacking [19,20], and patients without MS suffering from sleep disorders show 
equally high values on the fatigue scales (MFIS and FSS) [21]. 
Sleep disorders can lead to fatigue [21] and depression [16] and CPAP therapy can subsequently 
improve these symptoms in patients with sleep apnea [15,22]. This suggests that reduced HRQoL, 
fatigue and depression can be common features of sleep disorders. Due to the close and complex 
relationship between fatigue, depression and sleep disorders in MS, and the overlap of the used 
questionnaires [15], we cannot state if sleep disorders lead to depression and subsequently to decreased 
HRQoL in the “energy” and “emotional” area—or vice versa, if sleep disorders lead to reduced 
daytime functioning and, subsequently, to depression. 
Our findings underscore that sleep disorders should be considered an important confounder in all 
future studies investigating HRQoL in MS patients. 
4. Experimental Section 
4.1. Literature Search 
A literature search was performed until May 2015 in PubMed (http://www.ncbi.nlm.nih.gov/pubmed) 
with the following keywords: “multiple sclerosis AND Nottingham Health Profile” and “multiple 
sclerosis AND quality of life”. After reading the abstracts, only relevant articles were read. Moreover, 
the references of these articles were read and hand-searched for potentially relevant studies or articles 
as well. 
4.2. Patients 
We classified the 66 patients (21 men and 45 women aged 20–66 years) into four subgroups: no 
sleep disorder (NSD) (n = 17), insomnia (n = 17), periodic limb movement disorder (PLMD), restless 
legs syndrome (RLS) or SD due to leg pain (PLMD/RLS) (n = 24), and untreated obstructive sleep 
apnea (OSA) (n = 8). 
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Expanded Disability Status Scale (EDSS) [12] values ranged from zero to eight. For more 
demographic details please see the original article [1]. All patients completed the NHP [10], MFIS [13], 
BDI [14], and the PSQI [6] in a German validation [23–26]. 
The original study was approved by the local ethics committees (Charité University Medicine 
Berlin, Berlin, Germany and Ernst Moritz Arndt University Medicine, Greifwald, Germany, project 
identification code BB 03/08; 31 January 2008), and all participants gave written informed consent 
prior to the assessment. 
4.3. Data Collection 
Data collection and extraction from the questionnaires (NHP) was performed by the corresponding 
author (CV). The PSG data extraction from the original study and the extraction of all questionnaires 
were performed by the corresponding author as well [1]. 
4.4. Polysomnography and Scoring Criteria 
As described in our original article [1], we performed PSG using a mobile polysomnographic device 
worn on the body, which has been validated in three different sleep centers [27] (Somnocheck 2R&K, 
Weinmann Medical Technology; software: Somnolab; analysis software: Artisana, Hamburg, Germany) 
without a video or audio signal, but otherwise with full recording facilities as in a sleep laboratory. 
Measurements were made over a period of 8 h: C3/C4-EEG electrodes to the contralateral mastoid 
electrode, ground electrode, electrooculogram on the ipsilateral mastoid electrode, bipolar chin 
electromyogram (EMG) of the muscle mentalis or muscle submentalis (according to biosignals testing 
and anatomical conditions), nasal airflow, thoracic breathing, abdominal breathing, position sensor, snoring 
signal, pulse oxymetry, pulse, electrocardiogram, bipolar 2-point EMG electrodes on both anterior tibial 
muscles. Prior to each measurement, an impedance test and a biosignal test were performed. A sleep 
specialist who was blinded to the clinical situation and the questionnaires analysed PSGs. Visual 
classification of sleep stages took place manually in accordance with Rechtschaffen and Kales [28]. 
Respiratory events were manually classified using the diagnostic guidelines of the Task Force of the 
American Academy of Sleep Medicine [29]. Periodic leg movements were pre-classified by the 
equipment’s software and manually corrected using the Coleman criteria [30]. We also investigated the 
hypnogram: sleep efficiency, sleep onset latency, sleep stages, wake-time after sleep onset, number of 
waking events, number of changes in sleep stages, arousal index, periodic leg movement (PLM) index, 
PLM index in rapid-eye-movement (REM) sleep and non-REM sleep, PLM arousal index in REM 
sleep and non-REM sleep, respiratory disturbance index (RDI), blood oxygen desaturation, as well as 
chin EMG tonus, all respiratory events depending on position, arousal and sleep stage, and further 
standard polysomnographic parameters. Due to the first-night effect (patient is not yet familiar with the 
polysomnographic device), no pathological findings were assessed from the first-night hypnogram. On 
the first night, only PLMs and respiratory and cardiac events were considered. Following classification 
of the PSGs, sleep histories were obtained (CV), and a sleep diagnosis was made according to the 
International Classification of Sleep Disorders second edition (ICSD-2) [31]. To avoid false 
conclusions with respect to mild sleep disorders as possible causes of tiredness, mild insomnias, 
nocturia, mild PLMDs and sleep-related breathing disorders with RDI below 10 per hour were not 
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considered relevant sleep disorders. We classified as relevant sleep disorders only sleep disorders with 
disturbed hypnogram, which are able to cause consecutive daytime sleepiness. 
4.5. Statistical Analyses 
The results were expressed as mean, standard deviation, and range. Patients were classified into four 
subgroups by the presence of a sleep disorder. Following an exploratory analysis of the data the  
non-parametric Kruskal–Wallis-Test and subsequently the Mann–Whitney-U-Test for pairwise 
comparisons were performed. Non-parametric correlations (Spearman–Rho) were carried out. 
Statistical significance was established at p < 0.05. Due to the exploratory nature of the study, all 
tests were performed as exploratory data analyses, such that no adjustments for multiple testing have 
been made. Analysis was performed with SPSS software (IBM© SPSS© Statistics, Version 21, 
©Copyright 1989, 2010 SPSS Inc. an IBM Company, Chicago, IL, USA). 
5. Conclusions 
Sleep disorders can decrease HRQoL in MS patients—especially in the “energy” and “emotional” 
areas. In OSA patients, the “physical abilities” area can be negatively impacted as well. Future studies 
should investigate the impact of the treatment of sleep disorders on HRQoL in MS patients. 
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